- Proton Therapy for Hemithoracic Pleural Irradiation: A Step toward Safer Radiation Treatment
- Reprogramming T cell-myeloid crosstalk overcomes immune resistance in colorectal cancer
- Lung Cancer in Never Smokers: Genetics, Epidemiology, Environmental Exposures, and Distinct Immune Landscape
- Mismatch repair deficiency drives malignant progression and alters the tumor immune microenvironment in glioblastoma models
- Targeting neoantigens conserved across organs and species overcomes tumor immune escape
- The Role of Immunotherapy and Radiation Therapy in the Treatment of Breast Cancer
- Coordinated macrophage and T cell interactions mediate response to checkpoint blockade in colorectal cancer
- Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data
- An immunogenetic basis for lung cancer risk
- Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
Samstein RM*, Krishna C*, Ma X* et al. Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. Nature Cancer 2020 Nov 16. https://doi.org/10.1038/s43018-020-00139-8.
Mandal R*, Samstein RM*, Lee KW*, …, Chan TA. Genetic Diversity of Tumors with Mismatch Repair Deficiency Influences Tumor Evolution and Response to PD-1 Blockade. Science. 2019 May 3;364(6439):485-491.
Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, Kuo F, Kendall SM, Requena D, Riaz N, Greenbaum B, Carroll J, Garon E, Hyman DM, Zehir A, Solit D, Berger M, Zhou R, Rizvi NA, Chan TA. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 2018 Feb 2;359(6375):582-587.
Samstein RM*, Lee CH*, Shoushtari AN*, Hellman MD*, …, Riaz N, Morris LGT, Solit DB, Chan TA. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019 Feb;51(2):202-206.